Bibliography
- Druker BJ. Traslation of the Philadelphia chromosome into therapy for CML. Blood 2008;112:4808-17
- Ochi T, Fujiwara H, Suemori K, Aurora-A kinase: a novel target of cellular immunotherapy for leukemia. Blood 2009;113:66-74
- Katayama H, Brinkley WR, Sen S. The aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 2003;22:451-64
- Fu J, Bian M, Jiang Q, Zhang C. Roles of aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 2007;5:1-10
- Ducat D, Zheng Y. Aurora kinases in spindle assembly and chromosome segregation. Exp Cell Res 2004;301:60-7
- Hirota T, Kunitoku N, Sasayama T, Aurora-A and an interacting activator, the LIM protein ajuba, are required for mitotic commitment in human cells. Cell 2003;114:585-98
- Dutertre S, Cazales M, Quaranta M, Phosphorylation of CDC25B by aurora-A at the centrosome contributes to the G2–M transition. J Cell Sci 2004;117:2523-31
- Kufer TA, Sillje HH, Korner R, Human TPX2 is required for targeting aurora-A kinase to the spindle. J Cell Biol 2002;158:617-23
- Eyers PA, Erikson E, Chen LG, Maller JL. A novel mechanism for activation of the protein kinase aurora A. Curr Biol 2003;13:691-97
- Marumoto T, Honda S, Hara T, Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J Biol Chem 2003;278:51786-95
- Kunitoku N, Sasayama T, Marumoto T, CENP-A phosphorylation by aurora-A in prophase is required for enrichment of aurora-B at inner centromeres and for kinetochore function. Dev Cell 2003;5:853-64
- Littlepage LE, Wu H, Andresson T, Identification of phosphorylated residues that affect the activity of the mitotic kinase aurora-A. Proc Natl Acad Sci USA 2002;99:15440-45
- Walter AO, Seghezzi W, Korver W, The mitotic serine/threonine kinase Aurora2/AIK is regulated by phosphorylation and degradation. Oncogene 2000;19:4906-16
- Barr AR, Gergely F. Aurora-A: the maker and breaker of spindle poles. J Cell Sci 2007;120:2987-96
- Honda K, Mihara H, Kato Y, Degradation of human aurora2 protein kinase by the anaphase-promoting complex-ubiquitin-proteasome pathway. Oncogene 2000;19:2812-19
- Zhou H, Kuang J, Zhong L, Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998;20:189-93
- Tanaka E, Hashimoto Y, Ito T, The clinical significance of aurora-A/STK15/BTAK expression in human esophageal squamous cell carcinoma. Clin Cancer Res 2005;11:1827-34
- Klein UR, Nigg EA, Gruneberg U. Centromere targeting of the chromosomal passenger complex requires a ternary subcomplex of borealin, survivin, and the N-terminal domain of INCENP. Mol Biol Cell 2006;17:2547-58
- Bourhis E, Hymowitz SG, Cochran AG. The mitotic regulator survivin binds as a monomer to its functional interactor borealin. J Biol Chem 2007;282:35018-23
- Smith SL, Bowers NL, Betticher DC, Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability. Br J Cancer 2005;93:719-29
- Chen J, Li D, Wei C, Aurora-A and p16 polymorphisms contribute to an earlier age at diagnosis of pancreatic cancer in caucasians. Clin Cancer Res 2007;13:3100-04
- Bischoff JR, Anderson L, Zhu Y, A homologue of drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 1998;17:3052-65
- Sen S, Zhou H, White RA. A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene 1997;14:2195-200
- Tanaka T, Kimura M, Matsunaga K, Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Res 1999;59:2041-44
- Miyoshi Y, Iwao K, Egawa C, Noguchi S. Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int J Cancer 2001;92:370-73
- Takahashi T, Futamura M, Yoshimi N, Centrosomal kinases, HsAIRK1 and HsAIRK3, are overexpressed in primary colorectal cancers. Jpn J Cancer Res 2000;91:1007-14
- Reiter R, Gais P, Jutting U, Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin Cancer Res 2006;12:5136-41
- Tong T, Zhong Y, Kong J, Overexpression of aurora-A contributes to malignant development of human esophageal squamous cell carcinoma. Clin Cancer Res 2004;10:7304-10
- Sakakura C, Hagiwara A, Yasuoka R, Tumour-amplified kinase BTAK amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer 2001;84:824-31
- Li D, Zhu J, Firozi PF, Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res 2003;9:991-97
- Gritsko TM, Coppola D, Paciga JE, Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res 2003;9:1420-26
- Buschhorn HM, Klein RR, Chambers SM, Aurora-A over-expression in high-grade PIN lesions and prostate cancer. Prostate 2005;64:341-46
- Meraldi P, Honda R, Nigg EA. Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53–/– cells. EMBO J 2002;21:483-92
- Landen CN Jr, Lin YG, Immaneni A, Overexpression of the centrosomal protein aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. Clin Cancer Res 2007;13:4098-104
- Guan Z, Wang XR, Zhu XF, Aurora-A, a negative prognostic marker, increases migration and decreases radiosensitivity in cancer cells. Cancer Res 2007;67:10436-44
- Hamada M, Yakushijin Y, Ohtsuka M, Aurora2/BTAK/STK15 is involved in cell cycle checkpoint and cell survival of aggressive non-hodgkin's lymphoma. Br J Haematol 2003;121:439-47
- Camacho E, Bea S, Salaverria I, Analysis of aurora-A and hMPS1 mitotic kinases in mantle cell lymphoma. Int J Cancer 2006;118:357-63
- Ikezoe T, Yang J, Nishioka C, A novel treatment strategy targeting aurora kinases in acute myelogenous leukemia. Mol Cancer Ther 2007;6:1851-57
- Walsby E, Walsh V, Pepper C, Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. Haematologica 2008;93:662-69
- Huang XF, Luo SK, Xu J, Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in aurora-A-high acute myeloid leukemia. Blood 2008;111:2854-65
- Hata T, Furukawa T, Sunamura M, RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res 2005;65:2899-905
- Harrington EA, Bebbington D, Moore J, VX-680, a potent and selective small-molecule inhibitor of the aurora kinases, suppresses tumor growth in vivo. Nat Med 2004;10:262-67
- Carter TA, Wodicka LM, Shah NP, Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 2005;102:11011-16
- Rubin EH, Shapiro GI, Stein MN, A phase I clinical and pharmacokinetic (PK) trial of the aurora kinase (AK) inhibitor MK-0457 in cancer patients [abstract 3009]. J Clin Oncol 2006;24(Suppl 20)
- Giles FJ, Cortes J, Jones D, MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007;109:500-02
- Manfredi MG, Ecsedy JA, Meetze KA, Antitumor activity of MLN8054, an orally active small-molecule inhibitor of aurora A kinase. Proc Natl Acad Sci USA 2007;104:4106-11
- Jones SF, Cohen RB, Dees EC, Phase I clinical trial of MLN8054, a selective inhibitor of aurora A kinase. Proc Am Soc Clin Oncol Annu Meet 2007;25:3577
- Carpinelli P, Ceruti R, Giorgini ML, PHA-739358, a potent inhibitor of aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 2007;6:3158-68
- Gontarewicz A, Balabanov S, Keller G, Simultaneous targeting of aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 2008;111:4355-64
- De Jonge M. A phase I dose-escalation study of PHA-739358 administered as a 6-hour infusion on days 1, 8, and 15 every 4 weeks in patients with advanced/metastatic solid tumors. Presented at the VIII Congress of the Italian Association of Medical Oncology (AIOM), Milan, Italy; November 18 2006
- Bastos BR, Diamond J, Hansen R, An open-label, dose escalation, safety, and pharmacokinetic study of ENMD-2076 administered orally to patients with advanced cancer [abstract 3520]. J Clin Oncol 2009;27(Suppl 20)
- Huck JJ, Zhang M, Hyer ML, Manfredi MG. Anti-tumor activity of the aurora a inhibitor MLN8237 in diffuse large B-cell lymphoma preclinical models [abstract 1592]. Blood 2008;112(Suppl 16)
- Study of MLN8237 in adults with aggressive non-hodgkin's lymphoma. Clinical trials.gov. Bethesda, Maryland: US National Institutes of Health 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00807495. [Last accessed 15 September 2009]
- Cervantes-Ruiperez A, Elez ME, Roselló S, Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MLN8237, a novel selective aurora A kinase (AAK) inhibitor, in patients (pts) with advanced solid tumors [abstract 2565]. J Clin Oncol 2009;27(Suppl 20)
- Michor F, Hughes TP, Iwasa Y, Dynamics of chronic myeloid leukaemia. Nature 2005;435:1267-70
- Graham SM, Jorgensen HG, Allan E, Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002;99:319-25
- Bhatia R, Holtz M, Niu N, Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003;101:4701-07
- Chu S, Xu H, Shah NP, Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005;105:2093-98
- Shah NP, Skaggs BJ, Branford S, Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 2007;117:2562-69
- Gal H, Amariglio N, Trakhtenbrot L, Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells. Leukemia 2006;20:2147-54
- Diaz-Blanco E, Bruns I, Neumann F, Molecular signature of CD34+ hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia 2007;21:494-504
- Bruns I, Czibere A, Fischer JC, The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence. Leukemia 2009;23:892-99
- Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008;112:4371-83
- Molldrem JJ, Lee PP, Wang C, Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000;6:1018-23
- Rezvani K, Grube M, Brenchley JM, Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 2003;102:2892-900
- Kawakami Y, Eliyahu S, Delgado CH, Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91:3515-19
- Kawakami Y, Eliyahu S, Sakaguchi K, Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-52
- Stevens EJ, Jacknin L, Robbins PF, Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition. J Immunol 1995;154:762-71
- Cormier JN, Salgaller ML, Prevette T, Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1997;3:37-44
- Rao NV, Wehner NG, Marshall BC, Characterization of proteinase-3 (PR-3), a neutrophil serine proteinase. Structural and functional properties. J Biol Chem 1991;266:9540-48
- Dengler R, Munstermann U, al-Batran S, Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells. Br J Haematol 1995;89:250-57
- Molldrem J, Dermime S, Parker K, Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 1996;88:2450-57
- Qazilbash MH, Wieder ED, Thall PF, PR1 peptide vaccine-induced immune response is associated with better event-free survival in patients with myeloid leukemia [abstract 283]. Blood 2007;110:90a
- Call KM, Glaser T, Ito CY, Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 wilms' tumor locus. Cell 1990;60:509-20
- Inoue K, Sugiyama H, Ogawa H, WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994;84:3071-79
- Oka Y, Tsuboi A, Oji Y, WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol 2008;20:211-20
- Elisseeva OA, Oka Y, Tsuboi A, Humoral immune responses against wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 2002;99:3272-79
- Gao L, Bellantuono I, Elsasser A, Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000;95:2198-203
- Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000;95:286-93
- Guo Y, Niiya H, Azuma T, Direct recognition and lysis of leukemia cells by WT1-specific CD4+ T lymphocytes in an HLA class II-restricted manner. Blood 2005;106:1415-18
- Fujiki F, Oka Y, Tsuboi A, Identification and characterization of a WT1 (wilms tumor gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes. J Immunother 2007;30:282-93
- Oka Y, Tsuboi A, Taguchi T, Induction of WT1 (wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004;101:13885-90
- Keilholz U, Letsch A, Busse A, A clinical and immunological phase 2 trial of wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009;113:6541-8
- Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15
- Dudley ME, Wunderlich JR, Robbins PF, Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-54
- Yee C, Thompson JA, Byrd D, Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 2002;99:16168-73
- Bolanos-Garcia VM. Aurora kinases. Int J Biochem Cell Biol 2005;37:1572-77
- Yong AS, Keyvanfar K, Eniafe R, Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy. Leukemia 2008;22:1721-27
- Radich JP, Dai H, Mao M, Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 2006;103:2794-99
- Goyal RK, Lin P, Kanungo J, Ajuba, a novel LIM protein, interacts with Grb2, augments mitogen-activated protein kinase activity in fibroblasts, and promotes meiotic maturation of Xenopus oocytes in a Grb2- and Ras-dependent manner. Mol Cell Biol 1999;19:4379-89
- Rezvani K, Yong AS, Savani BN, Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood 2007;110:1924-32
- Katayama H, Ota T, Jisaki F, Mitotic kinase expression and colorectal cancer progression. J Natl Cancer Inst 1999;91:1160-62
- Chieffi P, Cozzolino L, Kisslinger A, Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation. Prostate 2006;66:326-33
- Schellens JH, Boss D, Witteveen PO, Phase I and pharmacological study of the novel aurora kinase inhibitor AZD1152 [abstract 3008]. J Clin Oncol 2006;24(Suppl 20)
- Bocchia M, Gentili S, Abruzzese E, Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 2005;365:657-62